MonumenTAL-1: Data Updates of Talquetamab, a GPRC5D-Directed Bispecific Antibody for RRMM

Treatment with anitocabtagene autoleucel produced durable efficacy in patients with relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Arlocabtagene autoleucel led to antitumor activity and an acceptable safety profile in heavily pretreated relapsed/refractory multiple myeloma, according to updated phase 1 trial data.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Lisaftoclax, a BCL-2 inhibitor, demonstrated efficacy and tolerability in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma as well as amyloidosis.

In a retrospective cohort of patients with central nervous system manifestations of multiple myeloma, ide-cel CAR T-cell therapy was effective.